

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CARsgen Therapeutics Holdings Limited

科濟藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2171)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2026

At the annual general meeting (the “AGM”) of CARsgen Therapeutics Holdings Limited (the “**Company**”) held on 22 May 2026, all the proposed resolutions, as set out in the notice of the AGM dated 10 April 2026 were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor of the Company for the year ended 31 December 2025.	148,663,558 (99.926734%)	109,000 (0.073266%)
2.	To re-elect Dr. Zonghai LI as an executive director of the Company.	144,013,987 (96.734798%)	4,861,071 (3.265202%)
3.	To re-elect Dr. Huamao WANG as an executive director of the Company.	148,132,410 (99.501160%)	742,648 (0.498840%)
4.	To re-elect Dr. Hua JIANG as an executive director of the Company.	148,132,410 (99.501160%)	742,648 (0.498840%)
5.	To authorize the board of directors of the Company to fix the remuneration of the directors of the Company.	148,809,558 (99.956003%)	65,500 (0.043997%)
6.	To re-appoint Ernst & Young as auditor of the Company and to authorize the board of directors of the Company to fix their remuneration.	148,874,058 (99.999328%)	1,000 (0.000672%)
7.	To grant a general mandate to the directors of the Company to allot, issue and deal with additional Shares and sell and/or transfer treasury shares not exceeding 20% of the number of issued Shares (excluding any treasury shares).	137,442,941 (92.320999%)	11,432,117 (7.679001%)
8.	To grant a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the number of issued Shares (excluding any treasury shares).	148,874,058 (99.999328%)	1,000 (0.000672%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
9.	To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 7 to issue shares by adding the number of shares repurchased under ordinary resolution no. 8.	137,442,941 (92.320999%)	11,432,117 (7.679001%)
Special Resolution		Number of Votes (%)	
		For	Against
10.	To approve the Proposed Amendments and the adoption of the Ninth Amended and Restated Memorandum and Articles of Association.	148,874,058 (99.999328%)	1,000 (0.000672%)

Notes:

- (a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 9, all these resolutions were duly passed as ordinary resolutions.
- (b) As more than 75% of the votes were cast in favour of resolution numbered 10, this resolution was duly passed as a special resolution.
- (c) The total number of shares of the Company in issue as at the date of the AGM was 578,778,248 shares.
- (d) As at the date of the AGM, KASTLE LIMITED, the trustee of the equity incentive plan and the post-IPO RSU scheme, abstained from voting at the AGM with respect to 24,604,802 shares of the Company held by it in accordance with Rule 17.05A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), and there were 7,818,000 treasury shares held by the Company (including any treasury shares held or deposited with Central Clearing and Settlement System) and 455,000 repurchased shares pending cancellation. Accordingly, the total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 545,900,446 shares.
- (e) Save as disclosed above, to the best of the knowledge, information and belief of the Board, and having made all reasonable enquiries, (i) there were no shares entitling the holder to attend but where the holder was required to abstain from voting in favour of any of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules; (ii) no shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM; and (iii) none of the shareholders of the Company have stated their intention in the Company’s circular dated 10 April 2026 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (f) The Company’s branch share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (g) Save for Dr. Wen ZHOU who did not attend the AGM due to other business commitments, all other directors of the Company either attended the AGM physically or by electronic means.

By order of the Board
CARsgen Therapeutics Holdings Limited
Dr. Zonghai LI
Chairman

Hong Kong, May 22, 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Huaqing GUO and Mr. Ronggang XIE as non-executive Directors; Dr. Guangmei YAN, Ms. Xiangke ZHAO and Dr. Wen ZHOU as the independent non-executive Directors.